NCT01343121View on ClinicalTrials.gov

Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 2, 2012

Primary Completion Date

November 24, 2017

Study Completion Date

November 24, 2017

Conditions
Bladder Cancer
Interventions
OTHER

sample collection

Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.

OTHER

sample collection

Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine

OTHER

Sample Collection

Quality of Life (QOL) questionnaires given to the patient at each visit

Trial Locations (1)

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

The Christie NHS Foundation Trust

OTHER

NCT01343121 - Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy | Biotech Hunter | Biotech Hunter